Three Consecutive Monthly Intravitreal Ranibizumab for Choroidal Neovascularization in Central Serous Choriorethinopathy:A Case Report

作     者：Kazim Erol Esin Sogutlu Sari Arif Koytak A.Karacor D.T.Coban M.Bulut 

作者机构：Ophthalmology DepartmentAntalya Training and Research HospitalAntalyaTurkey Ophthalmology DepartmentKartal Training and Research HospitalIstanbulTurkey Ophthalmology DepartmentBezmialem Vakif UniversityIstanbulTurkey 

出 版 物：《Open Journal of Ophthalmology》 (眼科学期刊（英文）)

年 卷 期：2012年第2卷第3期

页      面：93-96页

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Central Serous Choriorethinopathy Choroidal Neovascularization Ranibizumab 

摘      要：Purpose: The author report the result of three consecutive monthly intravitreal ranibizumab injection for choroidal neovascularization (CNV) after bevacizumab injection for chronic central serous rethinopathy (CSR). Methods: A 48 year old man with chronic CSR was treated with intravitreal single dose 2.5 mg bevacizumab. One year after CNV was occurred, and three consecutive monthly intravitreal ranibizumab injections were performed. Results: Four weeks later the first ranibizumab dose, best corrected visual acuity was improved 20/80 to 20/20 and remained stable within one year. Conclusion: Repeat intravitreal ranibizumab injection in CNV after bevacizumab injection for chronic CSR appeared to be an effective treatment option.